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Stable angina: historical and contemporary data
The classical description of Stable Angina, which 
is valid and today, has been made for the first time by 
William Beberdeb in 1772. His article about almost 
20 patients called “Some considerations about chest 
diseases”. He made a very detailed and excellent de-
scription, since the Stable Angina is called up today 
Heberden’s angina [1, 5]. He described very clear 
its precipitation to the effort and emotions. Hunter 
died suddenly, in 1793, at the age of 65, and at the 
autopsy made by his disciple Edward Jenner it was 
found the intense coronary artery ossification. These 
findings allowed the determination of a relation 
between Stable Angina and coronary disease [8, 9]. 
Then, in 1799, the scientist Parry linked the Stable 
Angina problem with the poor blood flow with the 
obstruction of the coronary arteries, and in 1809 the 
well-known scientist Bums said that Stable Angina 
develops because “offer of energy and exhaustion 
are not balanced”. This important conception re-
mains valid up today [5].
In 1933, the famous Britain cardiologist Sir 
Thomas Lewis launched the concept that ischemia 
includes not only changes in the structure of coro-
nary arteries, but and in and their tonicity, therefore 
a supply deficit may be caused by inadequate coro-
nary tone and the deficit can cup by vasodilation [7, 
9]. These methods remain today of major importance 
in the diagnosis of Stable Angina, very informative, 
accessible and safe at the same time [6, 7]. An impor-
tant step in the diagnosis ofthe Stable Angina was 
innovation in technique viewing of coronary arteries. 
Selective coronary angiography was introduced by 
MasonSones in 1959 in the United States. He relied 
on the works of German doctor Werner Forssmann, 
who in 1929 tried this method by himself by insert-
ing a catheter through the cubital vein to the right 
atrium. Later he and is honored with the Nobel Prize 
for developing the method of the human body 
probing. 
Angina particularities at men; Trigger-factors
The subclinical signs of atherosclerosis, such as 
thickness measurements intimates environments, 
can also identify women before menopause, es-
pecially when there are present some risk factors. 
Flow-mediated vasodilation of the brachial artery 
decreases with age at menopause. 
Dyslipidemia. Throughout life, men are subject 
to a number of hormonal changes, including those 
associated with puberty. Each of these variations can 
alter hormone levels in serum lipoproteins. At birth 
and during childhood cholesterol levels is the same 
for girls and boys. After the age of 20 years, in both 
sexes, LDL-cholesterol tends to increase, however, 
with a higher rate in men. Besides reducing overall 
levels of HDL cholesterol, and changes occur in the 
proportion of its subtypes, with obvious reduction 
HDL2 particle considered to be more active in the 
transport of cholesterol [2, 4]. 
Hypertriglyceridemia is also an independent 
risk factor for ICC stronger for men than women. A 
meta-analysis of 17 studies showed that the relative 
risk for hypertriglyceridemia CI was raised by 32% in 
men and 76% women. In the study Lipid Research 
Clinics’ Follow Up Study determined that the level 
of HDL-cholesterol and triglycerides are powerful 
predictors for the ICC to women than LDL and total 
cholesterol [1, 2].
Hypertension. Vasodilation is determined by 
the increase of bioviability of nitric oxide, inhibition 
of proliferation of smooth muscle cells in vessels, 
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inhibition of the renin-angiotensin-aldosterone 
system (RAAS), inhibition of the sympathetic nerv-
ous system [3]. At the same time, the menopause 
increases the risk of glomerulosclerosis and renal 
pathology because the decrease of estrogen level 
contributes to the proliferation of mesangial cells, so 
determining the glomerulosclerosis development, 
and later high blood pressure [1, 4]. Furthermore, the 
estrogens a strong antioxidant effect, inhibiting the 
generation of active forms of oxygen [4, 8], involved 
in the atherosclerosis generation. Men who have 
high rates of blood pressure already present a risk 
for IHD for time more than men who have optimal 
blood pressure. At the same time, the hypersensitive 
men who dispose of an adequate treatment have a 
risk for CI 8 times higher than normotensive men, 
meanwhile in men with an inadequate therapy the 
risk for IHD increase 19 times [7, 9].
Smoking. Although the majority of cardio-
vascular risks in women are aggravating during the 
postmenopausal period, the smoking has a harmful 
effect since the youth. In young women, the smoking 
causes a decrease of regulation by the estrogens of 
the endothelial wall vasodilation [5, 6]. By the age 
of 50, the smoking has a more negative effect in 
men than in women, depending on the number of 
cigarette packages smoked per day [93], presenting 
a higher risk to develop IHD [5, 7]. Its atherogenic risk 
is determined by a great number of mechanisms. 
It induces the coronary spasm, has prothrombotic 
properties, determines changes in the blood rhe-
ology, increases the oxidation of LDL-cholesterol, 
decreases the level of HDL-cholesterol, causes the 
platelet aggregation, increases the fibrinogen level, 
determines the endothelial deficiency etc. [2, 6]. 
An obvious risk factor represents and the passive 
smoking, responsible for the increase of risk for CI 
with 30% [1, 5, 9].
Body weight may increase during the first years 
of menopause and body fat distribution changes 
from a gynoid pattern to an android one. Given the 
fact that the distribution of fats plays a key role for 
the assessment of cardio-vascular risk, besides BMI 
it is important to determine also the waist-hip or 
abdominal circumference proportion. Men who 
have the waist-hip proportion >0.76, compared to 
men with <0.72, have a cardio-vascular risk 2.3 times 
higher, and women with the proportion >0.88 – 5 
times higher. Men with abdominal circumference 
>76.2 cm have 1.8 times higher cardio-vascular risk 
compared to women who have an abdominal cir-
cumference <71.1 cm, and for those who have the 
abdominal circumference >96.5 cm, the risk is 3.2 
times higher [1, 4].
The type 2 diabetes mellitus (DM) presents an 
important cardiovascular risk factor. In the most 
cases the DM is also associated with other risk factors, 
as: hypertriglyceridemia, hypertension, atherogenic 
dyslipidemia, inflammation and endothelial dysfunc-
tion, fibrinolysis [2, 5]. The studies emphasize that 
the cardiovascular risk of DM increases together with 
its evolution, being equal to zero in the first time 
after the diagnostic of DM and 7 times higher over 
7 years [4, 7]. Men with DM a subject to a 8 times 
higher cardiovascular risk than the non-diabetes 
population, meanwhile the men present a 3 times 
higher risk [4, 8]. The case of a so higher death rate 
in woman is multifactorial, associating the involve-
ment of inflammatory factors, the smaller coronary 
arteries and treatment of diabetes often lighter than 
for men [9].
Sedentary lifestyles. Physical inactivity is a ma-
jor atherogenic risk factor. A meta-analysis of several 
studies showed that physically active people have 
a likelihood of developing the IHD from 50 to 70% 
lower compared to physically inactive persons [1, 4, 
9]. The explanation for this phenomenon belongs to 
the improvement of lipid profile, insulin sensitivity 
and endothelial function of the coronary arteries. 
Treatment
Drug treatment: 
• Stopping smoking and avoiding contact
with smokers, which is associated with a reduction 
in mortality due to AMI 36% [2, 3]; 
• Observance of the Mediterranean diet, with 
the aim of reducing the BMI <25 kg/m2; 
• Regular physical activity – 30 minutes daily,
or minimum 3 times per week in patients with a his-
tory of MI or revascularization; 
• Sexual activity does not represent limitations
in patients with successful revascularization and 
those with NYHA I after grade IC, the remaining pa-
tients, it is necessary to perform a stress test to assess 
the degree of stress symptoms from occurring; 
• Management has favorable effects on body 
mass of BP control, dyslipidemia and glucose me-
tabolism; 
• Lipid management through lifestyle modi-
fication and/or administration of statins; 
• Maintaining BP within the norm: 130-139 /
80-85 mmHg; 
• Glucose monitoring within the norm, age, pres-
ence of diabetes complications and duration [1, 7].
Anti-ischemic therapy. Nitrates by means of 
the active compound, nitric oxide (NO) provides 
an arteriolar and venous vasodilation, thus improv-
ing coronary flow and at the same time decreasing 
the pre- and afterload. The standard treatment for 
angina attacks remains cropping of nitroglycerin in 
tablets (0.3-0.6 mg) or as a spray, sublingual every 
5 minutes, until the chest pain is improved (up to 
1.2 mg). Ivabradine lowers heart rate, inhibiting 
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selective sinus node, it decreases the myocardial 
oxygen need, with no effect on inotropism or TA [1, 
5, 4]. Nicorandil is a nicotinamide derivative, which 
dilates epicardial arteries of the heart and at the 
same time stimulate ATP-sensitive potassium chan-
nels. It is suitable both for prevention and for long-
term treatment of AP. Trimetazidine is a metabolic 
modulator anti-ischemic treatment very effective 
anti-anginal, but has a number of contraindications, 
such as Parkinson’s disease, motor disorders or 
diabetes. Ranolazine is a selective inhibitor of the 
Na flux with anti-ischemic and metabolic disorders. 
It reduces angina and increase functional capacity 
without altering heart rate or BP.
Pathogenetic therapy. Acetylsalicylic acid at 
a dose of 75-150 mg remains the foundation of 
pharmacological prevention of arterial thrombosis. 
Clopidogrel is the best option for patients with AMI, 
stroke (stroke) or a history of peripheral vascular 
disease. Prasugrel P2Y12 antagonists and Ticagrelor 
are new, with stronger antiplatelet effect, but not yet 
widely indicated, due to insufficient clinical studies 
[5, 9]. In women, aspirin decreased the risk of MI by 
12% and men 14% [1, 7]. Angiotensin-converting 
enzyme (ACE) is indicated, especially in patients 
with HF, diabetes, hypertension and / or LVEF (left 
ventricular ejection fraction) ≤40%. 
Lipid lowering therapy. Treatment with statins 
reduces the risk of atherosclerotic cardiovascular com-
plications in both primary prevention and secondary. 
In patients with atherosclerotic vascular disease, simv-
astatin and pravastatin reduced the incidence of seri-
ous cardiovascular complications by 30%. Other drugs 
that modify lipid profiles than the statins, for example, 
fibrates, nicotinic acid resin or extended release, and 
combinations thereof and other lipid-lowering statin 
may be required to control the level of fat in patients 
with severe dyslipidemia [4,5]. In women, statins have 
been shown to be more beneficial in the prevention 
of ICC, indicating a reduction in cardiovascular risk by 
25%, compared to males it has been found that only 
a 14% diminuating [1, 3, 6].
Coronary revascularization. Percutaneous 
transluminal coronary angioplasty (PTCA) is a 
method that has evolved from simple metal stents 
associated with a recurrence rate of 20-30% stenosis 
of pharmacologically active stents to reduce the 
incidence of restenosis coming and the need for 
further revascularization. Coronary angiography and 
percutaneous coronary intervention (PCI) are more 
commonly performed via the femoral or the radial 
artery and less commonly performed via the brachial 
or ulnar artery. Overall, the femoral artery is the most 
common route of access for these procedures in the 
United States; however, the use of radial access is 
increasing. In selected labs in the United States and 
in some parts of Europe, radial artery access exceeds 
90%. Subsequently, pharmacologically active stents 
have been improved by reducing the thickness strut 
site and using biocompatible polymers. To prevent 
stent thrombosis, patients received double antiplate-
let therapy is indicated for 6-12 months after surgery 
[9]. Coronary artery bypass surgery is a method of 
revascularization that by using arterial grafts (inter-
nal mammary artery) or venous (saphenous vein) 
allows by passing the obstruction and coronary flow 
restoration. 
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